Maravai LifeSciences (NASDAQ:MRVI – Get Rating) had its price objective lowered by research analysts at Robert W. Baird from $48.00 to $40.00 in a research report issued on Friday, The Fly reports. Robert W. Baird’s price objective suggests a potential upside of 40.11% from the stock’s previous close.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.